For instance, a high baseline level of circulating osteopontin was a predictor of poor clinical response and inferior PFS and/or OS in patients with nasopharyngeal cancer subjected to radiotherapy or concurrent chemoradiation [82], in non-small-cell lung cancer patients receiving platinum-based chemotherapy or nivolumab [83, 84], as well as in locally advanced or metastatic breast cancer patients treated with neoadjuvant chemotherapy [85] or docetaxel plus cisplatin or carboplatin [86], respectively. The gene discussed is SPP1; the disease is non-small cell lung carcinoma.